| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 6,713 | 7,797 | 7,184 | 2,910 |
| Accounts receivable, net | 181 | 161 | 239 | NaN |
| Prepaid expense and other current assets | 467 | 934 | 1,437 | 1,680 |
| Subscription receivable | NaN | NaN | 3,087 | NaN |
| Total current assets | 7,361 | 8,892 | 11,947 | 4,590 |
| Investments | 399 | 397 | NaN | NaN |
| Ppe | NaN | 93 | 93 | NaN |
| Nrx Segment | NaN | 23 | 23 | NaN |
| Dura Segment | NaN | 7 | 1 | NaN |
| Ppe | 306 | NaN | NaN | NaN |
| Less accumulated depreciation | 47 | 30 | 24 | NaN |
| Furniture and equipment, net | 259 | 63 | 69 | NaN |
| Right-of-use assets, net-Nonrelated Party | 743 | 414 | 107 | NaN |
| Right-of-use assets, net-Related Party | 193 | 219 | 243 | NaN |
| Intangible assets, net (provisional) | 879 | 925 | 1,777 | NaN |
| Goodwill (provisional) | 1,793 | 1,793 | 610 | NaN |
| Other assets | 276 | 253 | 243 | 248 |
| Total assets | 11,903 | 12,956 | 14,996 | 4,838 |
| Convertible note payable and accrued interest, current | NaN | 0 | 9,909 | 9,854 |
| Accounts payable | 4,399 | 4,270 | 4,257 | 3,630 |
| Accrued and other current liabilities | 11,280 | 11,337 | 9,875 | 9,974 |
| Insurance loan payable | NaN | 0 | 152 | 378 |
| Accrued clinical site costs | 340 | 351 | 351 | 351 |
| Warrant liabilities | 8,766 | 12,304 | 15,860 | 16,266 |
| Lease liability, short term-Nonrelated Party | 283 | 211 | 87 | NaN |
| Lease liability, short term-Related Party | 108 | 105 | 102 | NaN |
| Total current liabilities | 25,176 | 28,578 | 40,593 | 40,453 |
| Convertible note payable and accrued interest, long term | NaN | 0 | 0 | 0 |
| Lease liability, noncurrent-Nonrelated Party | 455 | 199 | 15 | NaN |
| Lease liability, noncurrent-Related Party | 88 | 116 | 143 | NaN |
| Total liabilities | 25,719 | 28,893 | 40,751 | 40,453 |
| Preferred stock-Nondesignated Preferred Stock | 0 | 0 | 0 | 0 |
| Preferred stock-Series AConvertible Preferred Stock | 0 | 0 | 0 | 0 |
| Common stock, 0.001 par value, 500,000,000 shares authorized 33,471,315 and 31,734,333 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 33 | 32 | 28 | 19 |
| Additional paid-in capital | 294,476 | 290,926 | 281,473 | 265,732 |
| Accumulated deficit | -308,325 | -306,895 | -307,256 | -301,366 |
| Total stockholders deficit | -13,816 | -15,937 | -25,755 | -35,615 |
| Total liabilities and stockholders' deficit | 11,903 | 12,956 | 14,996 | 4,838 |
NRX Pharmaceuticals, Inc. (NRXPW)
NRX Pharmaceuticals, Inc. (NRXPW)